志特新材(300986.SZ):擬與專業投資機構共同投資設立基金
格隆匯2月19日丨志特新材(300986.SZ)公佈,董事會同意公司與上海尖晶投資有限公司(簡稱“尖晶投資”)共同投資設立志特尖晶新材料數智化產業升級基金合夥企業(有限合夥)(暫定名,最終以市場監督管理部門覈準的名稱爲準,簡稱“基金”“合夥企業”),基金認繳出資總額爲人民幣20,000萬元,其中公司作爲有限合夥人以自有資金出資人民幣19,900萬元,佔基金認繳出資總額的99.50%。投資方向:主要投向建築產業數智化升級和新材料智能化研發等領域,聚焦前沿科技推動產業創新、智能轉型和提質增效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.